Sanofi, Regeneron Rheumatoid Arthritis Drug Proves Ineffective Against COVID-19 2020/09/01 08:03:08 Benzinga
Sanofi SA (NASDAQ: SNY ) announced Tuesday that its rheumatoid arthritis drug Kevzara, developed in partnership with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ), isn't effective against COVID-19. What Happened: The global Phase 3 trial involving the administration of the drug to severely- or critically-ill hospitalized patients didn't meet its “primary endpoint,” the drugmaker said in a statement . No statistically significant shortening of hospitalization was observed in the 420 people trial conducted in multiple countries outside the United States, according to the French drugmaker. “Although this trial did not yield the … Full story available on Benzinga.com
A Divergence Has Occurred In Healthcare 2020/08/31 13:29:27 Benzinga
For the first four months of the market’s cornavirus recovery, one of the key themes was the dominance of biotech. In the 15 weeks from the market’s lows on March 23 until July 17, the VanEck Vectors Biotech ETF (NYSE: BBH ) rallied nearly 60% and took in inflows of nearly $84 million. The fund flew past its previous all-time high of $141 to a new all-time high of $172 thanks to massive rallies in stocks like Amgen Inc (NASDAQ: AMGN ), Moderna Inc (NASDAQ: MRNA ), and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), all of which have made new all-time highs this summer. Much of this optimism has been driven by the development of vaccine and treatment candidates for COVID-19. Moderna has a $1.5 billion deal to supply the U.S. government with 100 million doses of its vaccine … Full story available on Benzinga.com
Regeneron Partners With Roche to Make Covid-19 Drug 2020/08/19 10:21:30 The Street
Regeneron teams with rival Roche to help make and distribute REGN-COV2, Regeneron's experimental Covid-19 treatment.
Regeneron Pharmaceuticals : provides update on fasinumab program | MarketScreener 2020/08/19 07:32:09 MarketScreener
Regeneron provides update on fasinumab program August 18, 2020 Regeneron will discontinue actively treating patients with fasinumab, which… | August 19, 2020
Regeneron, Roche Team Up To Supply Covid-19 Antibody Cocktail To World 2020/08/19 06:15:03 Smarter Analyst
Regeneron Pharma (REGN) and Roche (RHHBY) have announced that they will work together to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational anti-viral antibody … The post Regeneron, Roche Team Up To Supply Covid-19 Antibody Cocktail To World appeared first on Smarter Analyst .
Bank of America shares a simple stock-trading strategy with a track record of repeatedly beating the market — including the 20 companies that best exploit it now 2020/08/13 16:01:00 Business Insider
Savita Subramanian, the head of US equity and quantitative strategy for Bank of America, says betting against the top picks of hedge funds can be a surprisingly profitable tactic. She says that betting against the top 10 overweights of actively managed hedge funds and buying the stocks the hedge funds like the least has been a way to beat the market recently. Hedge funds' top picks have offered mixed performance in recent months. Click here to sign up for our weekly newsletter Investing Insider . Visit Business Insider's homepage for more stories . Some days it's just more fun to be a contrarian and say "no" when everyone else is saying "yes." Fortunately, you can make money that way, too. Bank of America says there's a pretty simple way to do it based on the choices made by the managers of active hedge funds. Yes, you can copy their strategies and make money when they do, but you can also bet against them and wait for the laws of markets and gravity to profit when the least-loved stocks start to outperform. "Buying the 10 most underweight stocks and selling the 10 most overweight stocks by active funds has generated alpha in most years," wrote Savita Subramanian, the head of US equity and quantitative strategy, in a note to clients.
Regeneron Pharmaceuticals : Gets FDA Priority Review of Evinacumab | MarketScreener 2020/08/12 11:47:02 MarketScreener
By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted priority review to its biologics license application for evinacumab in… | August 12, 2020
Regeneron’s Covid-19 Treatment Could Be as Big a Deal as a Vaccine 2020/08/10 18:11:00 MarketWatch
Biotech Regeneron Pharmaceuticals has a cocktail of antibodies for treating Covid-19. Cannacord analyst John Newman says the treatment is “critical” because…
Regeneron profit beats on Dupixent strength 2020/08/05 11:29:45 Reuters
Regeneron Pharmaceuticals Inc beat second-quarter profit estimates on Wednesday, spurred by higher sales of its blockbuster eczema treatment Dupixent, and higher revenues connected to its collaboration with Sanofi SA and Bayer AG .
Regeneron Pharma posts quarterly profit on $228 million gain 2020/08/05 11:05:06 Investing.com
GlobalData : Despite temporary increased drug sales for most big bio/pharma companies, Regeneron Pharmaceuticals falls short of Q1 2020 forecast, says GlobalData | MarketScreener 2020/06/25 07:19:38 MarketScreener
25 Jun 2020 Despite temporary increased drug sales for most big bio/pharma companies, Regeneron Pharmaceuticals falls short of Q1 2020 forecast, says GlobalData … | June 25, 2020
Justice Department Sues Regeneron Over Payments to Copay-Assistance Charity | MarketScreener 2020/06/24 18:56:02 MarketScreener
By Peter Loftus The U.S. Justice Department sued Regeneron Pharmaceuticals Inc., accusing the drugmaker of paying kickbacks to a charitable foundation to boost sales of its high-selling… | June 24, 2020
U.S. claims Regeneron paid kickbacks via charity to boost expensive drug 2020/06/24 17:31:49 Reuters
The U.S. Justice Department on Wednesday sued Regeneron Pharmaceuticals Inc , accusing it of using a charity that helps cover Medicare patients' drug costs as a means to pay kickbacks for using its expensive macular degeneration drug Eylea.
Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug 2020/06/22 11:32:53 Smarter Analyst
French drugmaker Sanofi (SNYNF) has received regulatory approval in China for its Dupixent drug, which it is developing together with Regeneron Pharmaceuticals, Inc … The post Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug appeared first on Smarter Analyst .
Regeneron Pharmaceuticals : , Sanofi Dupixent Single-Dose Pen Approved By FDA | MarketScreener 2020/06/19 18:10:02 MarketScreener
By Chris Wack Regeneron Pharmaceuticals Inc. and Sanofi said Friday the U.S. Food and Drug Administration has approved a 300-mg single-dose pre-filled pen for Dupixent dupilumab. The… | June 19, 2020